AR101 Oral Immunotherapy for Peanut Allergy

• Published in: The New England journal of medicine Vol. 379; no. 21; pp. 1991 - 2001
• Main Authors: Vickery, Brian P, Vereda, Andrea, Casale, Thomas B, Beyer, Kirsten, du Toit, George, Hourihane, Jonathan O, Jones, Stacie M, Shreffler, Wayne G, Marcantonio, Annette, Zawadzki, Rezi, Sher, Lawrence, Carr, Warner W, Fineman, Stanley, Greos, Leon, Rachid, Rima, Ibáñez, M Dolores, Tilles, Stephen, Assa’ad, Amal H, Nilsson, Caroline, Rupp, Ned, Welch, Michael J, Sussman, Gordon, Chinthrajah, Sharon, Blumchen, Katharina, Sher, Ellen, Spergel, Jonathan M, Leickly, Frederick E, Zielen, Stefan, Wang, Julie, Sanders, Georgiana M, Wood, Robert A, Cheema, Amarjit, Bindslev-Jensen, Carsten, Leonard, Stephanie, Kachru, Rita, Johnston, Douglas T, Hampel, Jr, Frank C, Kim, Edwin H, Anagnostou, Aikaterini, Pongracic, Jacqueline A, Ben-Shoshan, Moshe, Sharma, Hemant P, Stillerman, Allan, Windom, Hugh H, Yang, William H, Muraro, Antonella, Zubeldia, José M, Sharma, Vibha, Dorsey, Morna J, Chong, Hey J, Ohayon, Jason, Bird, J Andrew, Carr, Tara F, Siri, Dareen, Fernández-Rivas, Montserrat, Jeong, David K, Fleischer, David M, Lieberman, Jay A, Dubois, Anthony E J, Tsoumani, Marina, Ciaccio, Christina E, Portnoy, Jay M, Mansfield, Lyndon E, Fritz, Stephen B, Lanser, Bruce J, Matz, Jonathan, Oude Elberink, Hanneke N G, Varshney, Pooja, Dilly, Stephen G, Adelman, Daniel C, Burks, A Wesley
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 22.11.2018
• Subjects: Administration, Oral; Adolescent; Adolescents; Adult; Adults; Age; Age Factors; Allergens - administration & dosage; Allergens - adverse effects; Arachis - adverse effects; Biological Products - administration & dosage; Biological Products - adverse effects; Biological Products - immunology; Child; Child, Preschool; Children; Desensitization, Immunologic - adverse effects; Desensitization, Immunologic - methods; Dose-Response Relationship, Immunologic; Double-Blind Method; Female; Food allergies; Gastrointestinal Diseases - etiology; Humans; Immunotherapy; Male; Middle Aged; Peanut Hypersensitivity - therapy; Peanuts; Pediatrics; Plant Proteins - administration & dosage; Plant Proteins - adverse effects; Plant Proteins - immunology; Young Adult
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1812856

A peanut-derived protein product, AR101, used in an oral desensitization protocol in children and adolescents with severe peanut allergy increased the amount of oral peanut protein tolerated in approximately two thirds of participants who received AR101, as compared with 1 of 25 controls.